# TARS catalysts: Tarsus Pharmaceuticals, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/tars/catalysts

> Tarsus Pharmaceuticals, Inc. (TARS) has 13 upcoming catalysts. The next is the Xdemvy (lotilaner) topline data readout, Dec 2026 to Mar 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Tarsus Pharmaceuticals, Inc. |
| Ticker | TARS (Nasdaq) |
| SEC CIK | 1819790 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/tars |

## Cash runway

Cash $316.3M as of 2026-09-30; quarterly burn $6.0M; about 158.1 months of runway at that rate (XBRL company facts, accession 0001819790-26-000076).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2022 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed, positive | "In May 2022, we announced positive topline results of the Saturn-2 trial, our second XDEMVY pivotal trial." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000011/tars-20241231.htm)) |
| Dec 2022 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed, positive | "In December 2022, we announced positive topline results from the completed Phase 1 Callisto trial (the "Callisto trial") and enrollment of the first patient in the Phase 2a clinical trial (the "Carpo trial")." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000011/tars-20241231.htm)) |
| Dec 2022 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed, positive | "With respect to Lyme disease, in December 2022 we announced positive topline results from the completed Callisto trial and enrollment of the first patient in the Carpo Trial." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000121/tars-20250930.htm)) |
| Mar 2023 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | rosacea | completed, positive | "In March 2023, we announced positive topline results from the Phase 1 Galatea trial (the "Galatea Phase 1 trial") and initiated a Phase 2a trial (the "Galatea trial") for the potential treatment of papulopustular rosacea." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000019/tars-20251231.htm)) |
| July 24, 2023 | [Xdemvy (lotilaner) FDA approval](https://sec-api.dev/pdufa/lotilaner) | TARS | To treat Demodex blepharitis | completed, approved | "Xdemvy \| lotilaner \| 7/25/2023 \| To treat Demodex blepharitisDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| September 30, 2023 | [Tarsus Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed, approved | "We began generating product sales during the three months ended September 30, 2023 following the FDA approval of XDEMVY in July 2023 and our subsequent commercial launch in August 2023." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979024000129/tars-20240930.htm)) |
| Dec 2023 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | MGD in patients with Demodex mites | completed, positive | "In December 2023, we announced positive topline results of the Ersa Trial evaluating XDEMVY administered twice daily ("BID") or three times a day ("TID") for 6 weeks and 12 weeks for the treatment of MGD in patients with Demodex mites." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000076/tars-20260930.htm)) |
| December 31, 2023 | [Tarsus Pharmaceuticals, Inc. FDA approval](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed, approved | "We began generating product sales during the year ended December 31, 2023, following the FDA approval of XDEMVY in July 2023 and our subsequent commercial launch in August 2023." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000011/tars-20241231.htm)) |
| Feb 2024 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | ocular rosacea | completed, positive | "In February 2024 we announced positive topline results, and in January 2025 we announced plans to initiate a Phase 2 study specifically for the potential treatment of ocular rosacea in the second half of 2025, which we expect to initiate in December 2025, with topline results expected by year-end 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000121/tars-20250930.htm)) |
| Feb 2024 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | rosacea | completed, positive | "In February 2024, we announced positive topline results from the Galatea trial, a Phase 2a trial evaluating TP-04, an investigational sterile aqueous gel formulation of lotilaner, for the potential treatment of papulopustular rosacea, for which Demodex mites is believed to be one of the root causes." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000076/tars-20260930.htm)) |
| Feb 2024 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | rosacea | completed, positive | "In February 2024, we announced positive topline results from the Carpo Trial, which demonstrated a statistically significant increase in tick mortality compared to vehicle (p<0.001), regardless of treatment arm, and was well tolerated (the "Carpo Trial")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000076/tars-20260930.htm)) |
| November 13, 2024 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979024000127/exhibit991tarsus11132024pr.htm)) |
| February 25, 2025 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000007/exhibit991tarsus2252025pre.htm)) |
| May 1, 2025 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000077/exhibit991tarsus512025pres.htm)) |
| August 6, 2025 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000107/exhibit991tarsus862025pres.htm)) |
| November 4, 2025 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/exhibit991tarsus1142025pre.htm)) |
| February 23, 2026 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000017/exhibit991tarsus2232026pre.htm)) |
| May 6, 2026 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/exhibit991tarsus562026.htm)) |
| August 6, 2026 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000063/exhibit991tarsus862026.htm)) |
| late 2026 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | ocular rosacea | scheduled | "◦A Phase 2 study of TP-04 (lotilaner ophthalmic gel) for the potential treatment of ocular rosacea (OR), a highly prevalent and underserved eye disease with no FDA-approved therapy, in December 2025, with topline data expected by year-end 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979025000120/exhibit991tarsus1142025pre.htm)) |
| November 3, 2026 | [Tarsus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/tars/catalysts) | TARS |  | completed | "Tarsus Reports Third Quarter 2026 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000074/exhibit991tarsus1132026.htm)) |
| Dec 2026 to Mar 2027 | [Xdemvy (lotilaner) topline data readout](https://sec-api.dev/pdufa/lotilaner) | TARS | Ocular Rosacea | scheduled | "NCT07443202 (Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07443202)) |
| December 2026 | [Xdemvy (lotilaner) primary completion](https://sec-api.dev/pdufa/lotilaner) | TARS | Ocular Rosacea | scheduled | "NCT07443202 (Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07443202)) |
| 1H 2027 | [IRX-101 topline data readout](https://sec-api.dev/pdufa/irx-101) | TARS | ocular rosacea, continues to progress, with topline data | scheduled | "Topline results are expected in the first half of 2027 and are anticipated to support a Phase 3-ready package." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000074/exhibit991tarsus1132026.htm)) |
| 1H 2027 | [IRX-101 trial start](https://sec-api.dev/pdufa/irx-101) | TARS |  | scheduled | "◦IRX-101: Plan to initiate the Phase 3 Comfort study evaluating an investigational ocular antiseptic for patients receiving intravitreal injections in the first half of 2027, with topline results expected in 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000074/exhibit991tarsus1132026.htm)) |
| 1H 2027 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | ocular rosacea with topline results | scheduled | "Initiated Calliope, a Phase 2 trial of TP-05, a novel investigational oral tablet for the potential prevention of Lyme disease, with topline data expected in the first half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/exhibit991tarsus562026.htm)) |
| 1H 2027 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | ocular rosacea, with topline results | scheduled | "The Kore Trial continues to progress, with topline results expected in the first half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000076/tars-20260930.htm)) |
| 1H 2027 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS |  | scheduled | "Topline data is expected in the first half of 2027, with the potential to support a Phase 3-ready package." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000037/exhibit991tarsus562026.htm)) |
| October 2027 | [Tp-05 (lotilaner) low dose primary completion](https://sec-api.dev/pdufa/tp-05-lotilaner) | TARS | Lyme Disease | scheduled | "NCT07562087 (A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07562087)) |
| Oct 2027 to Jan 2028 | [Tp-05 (lotilaner) low dose topline data readout](https://sec-api.dev/pdufa/tp-05-lotilaner) | TARS | Lyme Disease | scheduled | "NCT07562087 (A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07562087)) |
| 2028 | [IRX-101 topline data readout](https://sec-api.dev/pdufa/irx-101) | TARS |  | scheduled | "◦IRX-101: Plan to initiate the Phase 3 Comfort study evaluating an investigational ocular antiseptic for patients receiving intravitreal injections in the first half of 2027, with topline results expected in 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000074/exhibit991tarsus1132026.htm)) |
| Jul to Oct 2028 | [TP-06 topline data readout](https://sec-api.dev/pdufa/tp-06) | TARS | Persistent Corneal Epithelial Defect | scheduled | "NCT07886268 (A Study to Evaluate the Efficacy and Safety of TP-06 for PCED): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-07 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07886268)) |
| July 2028 | [TP-06 primary completion](https://sec-api.dev/pdufa/tp-06) | TARS | Persistent Corneal Epithelial Defect | scheduled | "NCT07886268 (A Study to Evaluate the Efficacy and Safety of TP-06 for PCED): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-07-07 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07886268)) |
| 2H 2029 | [IRX-101 topline data readout](https://sec-api.dev/pdufa/irx-101) | TARS | Stargardt disease, with topline results | scheduled | "and over seven years of long-term tolerability data Top-line Phase 3 NORTHSTAR data expected in the second half of 2029" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000060/acquisitionannouncementf.htm)) |

## Drugs

- [IRX-101](https://sec-api.dev/pdufa/irx-101): ocular rosacea continues to progress, with topline data, stargardt disease, with topline results, ocular rosacea, continues to progress, with topline data
- [Xdemvy (lotilaner)](https://sec-api.dev/pdufa/lotilaner): To treat Demodex blepharitis, Ocular Rosacea
- [Tp-05 (lotilaner) low dose](https://sec-api.dev/pdufa/tp-05-lotilaner): Lyme Disease
- [TP-06](https://sec-api.dev/pdufa/tp-06): Persistent Corneal Epithelial Defect

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/tars/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TARS catalysts: Tarsus Pharmaceuticals, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/tars/catalysts

```bibtex
@misc{secapidev_companies_tars_catalysts_20261116,
  title        = {TARS catalysts: Tarsus Pharmaceuticals, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/tars/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_tars_catalysts_20261116","title":"TARS catalysts: Tarsus Pharmaceuticals, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/tars/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
